Persistence of hepatitis C virus in patients successfully... : Hepatology (original) (raw)

VIRAL HEPATITIS

Radkowski, Marek1,2; Gallegos-Orozco, Juan F.1; Jablonska, Joanna2; Colby, Thomas V.1; Walewska-Zielecka, Bozena3; Kubicka, Joanna2; Wilkinson, Jeffrey1; Adair, Debra1; Rakela, Jorge1; Laskus, Tomasz*,1,§

1_Department of Medicine, Mayo Clinic Scottsdale, Scottsdale, AZ_

2_Institute of Infectious Diseases, Medical Academy, Warsaw, Poland_

3_National Institute of Hygiene, Warsaw, Poland_

*Division of Transplantation Medicine, SC Johnson Bldg Sj3, Mayo Clinic, Scottsdale, AZ 85259. fax: 480-301-3384

Received June 08, 2004; accepted October 10, 2004

See Editorial on Page 23

Conflict of interest: Nothing to report.

E-mail:[email protected]

Abstract

It is unclear whether the current antiviral treatment for chronic hepatitis C virus (HCV) infection results in complete elimination of the virus, or whether small quantities of virus persist. Our study group comprised 17 patients with chronic HCV who had sustained virological response (SVR) after interferon/ribavirin treatment. Serum and peripheral blood mononuclear cells were collected 2 to 3 times at 3- to 6-month intervals starting 40 to 109 months (mean, 64.2 ± 18.5 months) after the end of therapy. In addition, lymphocyte and macrophage cultures were established at each point. In 11 patients, frozen liver tissue samples were available from follow-up biopsies performed 41 to 98 months (mean, 63.6 ± 16.7 months) after therapy. Presence of HCV RNA was determined by sensitive reverse-transcriptase polymerase chain reaction, and concentration of positive and negative strands was determined by a novel quantitative real-time reverse transcriptase polymerase chain reaction. Only 2 of 17 patients remained consistently HCV RNA negative in all analyzed compartments. HCV RNA was detected in macrophages from 11 patients (65%) and in lymphocytes from 7 patients (41%). Viral sequences were also detected in 3 of 11 livers and in sera from 4 patients. Viral replicative forms were found in lymphocytes from 2 and in macrophages from 4 patients. In conclusion, our results suggest that in patients with SVR after therapy, small quantities of HCV RNA may persist in liver or macrophages and lymphocytes for up to 9 years. This continuous viral presence could result in persistence of humoral and cellular immunity for many years after therapy and could present a potential risk for infection reactivation. (Hepatology 2005;41:106–114.)